Lupin gains on US approval for eye drop generic

Shares in Lupin Ltd gained 3.2 per cent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the US regulator.

Gatifloxacin treats conjunctivitis, or more commonly called pink eye, and is produced by Allergan Inc.

A Lupin spokesman was not immediately reachable for comment.

Copyright: Thomson Reuters 2013